文献速递贫血与红细胞疾病

阵发性睡眠性血红蛋白尿症合并缺铁性贫血患者补铁治疗的疗效与安全性评价

[Evaluation of the efficacy and safety of iron therapy in patients with paroxysmal nocturnal hemoglobinuria complicated with iron deficiency anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

回顾性分析48例PNH合并缺铁性贫血患者,30例口服补铁、18例静脉补铁。口服补铁应答率56%(20/36),血红蛋白较基线中位升高21(10-52)g/L;静脉补铁16/18(89%)应答,6例口服无效者中5例静脉补铁后血红蛋白升高。补铁后LDH增高、尿色加深,未发生血栓及药物相关严重不良反应。

要点

  • PNH合并缺铁性贫血患者口服补铁应答率56%(20/36),血红蛋白较基线中位升高21(10-52)g/L。
  • 静脉补铁应答率89%(16/18),6例口服补铁无效者中5例静脉补铁后血红蛋白升高。
  • 补铁后LDH增高、尿色加深,未发生血栓及药物相关严重不良反应。

核心结论

  • 补铁治疗可有效提高PNH合并缺铁性贫血患者的血红蛋白水平,口服补铁疗效不佳时静脉补铁仍可作为有效治疗措施。
  • 补铁治疗合并铁缺乏的经典型PNH不良反应轻微。

研究设计与样本

  • 回顾性分析2011年11月至2018年8月连续收治的48例PNH合并缺铁性贫血患者,男29例、女19例,中位年龄32(1~62)岁。
  • 30例仅口服补铁治疗,18例接受静脉补铁治疗,其中12例初始即静脉补铁、6例口服补铁无效后再应用静脉补铁。

主要发现

  • 48例患者中位粒细胞PNH克隆大小为90.2%(38.5%~99.9%),红细胞PNH克隆大小为69.7%(27.6%~98.1%)。
  • 30例口服补铁患者中56%(20/36)获得血液学反应,HGB较基线中位升高21(10~52)g/L。
  • 18例静脉补铁患者中16例(89%)获得血液学反应;6例口服补铁未获血液学反应者,静脉补铁后5例获得血液学反应。
  • 补铁治疗后患者血清LDH水平明显增高、尿色加深,余不良反应轻微。
  • 未发生血栓并发症及药物相关的严重不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of iron supplement in patients who have paroxysmal nocturnal hemoglobinuria (PNH) with iron deficiency. Methods: We performed analyses on the clinical data of 48 patients who accepted oral and/or intravenous iron treatment. Forty-eight consecutive PNH patients with iron deficiency who visited our hospital between November 2011 and August 2018 were enrolled in the study. Results: Total 30 patients received oral iron; 18 patients received intravenous iron supplements, including 6 who did not respond to oral iron. The median PNH clone size was 90.2% (38.5%-99.9%) in the granulocytes and 69.7% (27.6%-98.1%) in the red blood cells. The response rate was 56% (20/36) in patients who received oral iron, and the hemoglobin concentration increased 21 (10-52) g/L compared to that at baseline. Sixteen out of eighteen (89%) patients responded to intravenous iron; 6 patients who did not respond to oral iron received intravenous iron, and the hemoglobin level of 5 patients increased. Patients exhibited increased LDH levels and deepen urine after iron supplementation; however, no severe adverse events, such as thrombosis and iron-related adverse effects, were noted. Conclusion: Iron treatment is safe and effective in increasing the hemoglobin level in PNH patients with iron deficiency; those who did not respond to oral iron could benefit from intravenous iron supplement. 目的: 分析阵发性睡眠性血红蛋白尿症(PNH)合并缺铁性贫血(IDA)患者补铁治疗的疗效及安全性。 方法: 回顾性分析2011年11月至2018年8月连续收治的48例PNH合并IDA患者,男29例、女19例,中位年龄32(1~62)岁。评估口服/静脉补铁治疗的疗效及安全性。 结果: 48例PNH合并IDA患者中,30例仅口服补铁治疗,18例接受静脉补铁治疗(12例初始即静脉补铁治疗,6例口服补铁治疗无效后再应用静脉补铁治疗)。48例患者中位粒细胞PNH克隆大小为90.2%(38.5%~99.9%)、红细胞PNH克隆大小为69.7%(27.6%~98.1%)。30例口服补铁治疗患者中,56%(20/36)获得血液学反应,HGB较基线中位升高为21(10~52)g/L。18例静脉补铁治疗患者16例(89%)获得血液学反应,其中6例口服补铁治疗未获血液学反应者,静脉补铁治疗后5例获得血液学反应。补铁治疗后患者血清LDH水平明显增高,尿色加深,余不良反应轻微,未发生血栓并发症及药物相关的严重不良反应。 结论: PNH合并IDA患者经补铁治疗可有效提高HGB水平;口服补铁治疗疗效不佳时,静脉补铁治疗仍可作为有效治疗措施;补铁治疗合并铁缺乏经典型PNH不良反应轻微。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Peng GX, Zhang L, Yang WR, et al. [Evaluation of the efficacy and safety of iron therapy in patients with paroxysmal nocturnal hemoglobinuria complicated with iron deficiency anemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32942822. doi:10.3760/cma.j.issn.0253-2727.2020.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。